Physician profile
Philip Clements
NPI 1518030873
$772.16
in general payments reported to CMS, 2019-2025
16 companies · $36.30 in 2025
The $36.30 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $54.88 · 2021: $83.98 · 2022: $131 · 2023: $170 · 2024: $78.05 · 2025: $36.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $104.83 | 2022-2023 | Lo Loestrin Fe |
| Therapeuticsmd, INC. | $88.68 | 2020-2022 | |
| Coopersurgical, INC. | $81.18 | 2019 | |
| Pfizer INC. | $80.47 | 2021-2024 | |
| Organon LLC | $78.84 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $68.51 | 2023 | Myrbetriq, Veozah |
| Avion Pharmaceuticals | $54.38 | 2019 | |
| Lupin INC. | $50.05 | 2019 | |
| Novo Nordisk INC | $44.86 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $21.23 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2023 | |
| Exeltis, USA INC. | $18.43 | 2024 | Slynd |
| Covidien LP | $17.40 | 2019 | |
| Mayne Pharma Commercial LLC | $15.48 | 2022 | |
| Hologic Sales and Service, LLC | $15.45 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.25 | 2024 | Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.